Time's ticking this morning so let's jump in quickly.


Breaking News Could Draw Huge Attention To Low Float (RNXT) Early Today (Nasdaq - Bullish Technicals)

March 8th

Greetings Readers,

Time's ticking this morning so let's jump in quickly.

Watching this profile closely in recent days, it just set a new 52-week high Tuesday.

But with today's breaking news, that 52-week high could be shattered today.

Check it out:

RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGemTM as a Treatment Option for Locally Advanced Pancreatic Cancer

Positive Trend in Median Overall Survival Versus Standard of Care, Warrants Continuation of the Pivotal Trial

Full Data Presentation, April 17, 2023, at the 2023 American Association of Cancer Research (AACR) Annual Meeting

LOS ALTOS, Calif., March 08, 2023--(BUSINESS WIRE)--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced promising interim data in the Phase III open label TIGeR-PaC clinical trial. The study is investigating the Company’s first product candidate, RenovoGem, as a potential treatment option in locally advanced pancreatic cancer ("LAPC").


"We are pleased with the promising readout of our study’s first interim analysis, and we extend our sincere and continued strong appreciation to all the patients, investigators, and team members involved in reaching this important milestone," said Shaun Bagai, CEO of RenovoRx. "Based on these data, we will continue our ongoing clinical trial to collect more data to support our new drug application. Our team intends to engage further with the FDA to facilitate an expeditious path forward for our treatment platform."

Bagai added, "Our mission is to transform the current standard of care for patients diagnosed with difficult-to-treat cancers, such as LAPC. The trend has been to layer additional drugs to the current standard of care that can double, triple, or quadruple, drug regimen for these patients. Our vision is to greatly improve existing treatment drugs by focusing on their targeted delivery to tumors, and, ultimately, improve quality of life and survival."


Read the full article here.

Based on this news, over 10+ triggered technicals on Barchart's site, a low float of fewer than 7Mn shares, and huge news in regards to corporate updates and a new patent (8 in total), this company requires immediate attention today.

Drop everything and get this Nasdaq profile on radar this second:

*RenovoRx, Inc. (RNXT)*

RenovoRx is a clinical-stage biopharmaceutical company with a vision to disrupt the current paradigm of cancer treatment. Their mission is to lead a revolution in oncology therapy by delivering its innovative and targeted intra-arterial (IA) delivery of chemotherapy directly to solid tumors.

And right now, RNXT has multiple potential catalysts that could spark a near term breakout:

No. 1 - Low Float Could Provide Significant Volatility Potential On Daily Basis

No. 2 - Triggered Technicals Galore Across The Short, Medium, And Long Term

No. 3 - Game-Changing Results Could Be Only Days Away...

No. 4 - USPTO Issues Company's Eighth US Patent

But more on those in a second...

RNXT: Addressing a Significant Problem in Cancer Treatment

Hypervascular tumors are adequately treated with current therapies

Liver tumors are highly vascularized

  • Large tumor feeders – excellent targets for systemic therapy
  • Can be accessed and treated with current local therapy techniques

Hypovascular tumors = major barrier to chemotherapy treatment success

Pancreatic tumors have poor blood supply

  • No visible tumor feeder vessels
  • Systemic chemotherapy does not reach tumor tissue
  • Inability to identify or engage tumor feeder vessels: local therapy is ineffective

RNXT Solution: Trans-Arterial Micro-Perfusion (RenovoTAMP)




RenovoGem™ Intra-Arterial Gemcitabine + RenovoCath® (FIRST PRODUCT CANDIDATE—REGULATED AS A DRUG)

Targeted Approach: designed to decrease side effects and increase tumor penetration

  • Reduced systemic drug exposure (compared to systemic chemotherapy)
  • Higher local drug concentration

Phase III Lead Drug Product Candidate: RenovoGem

  • Drug/Device Combination: Intra-arterial gemcitabine (chemotherapy) delivered through FDA cleared RenovoCath delivery system
  • Initial Phase I/II and observational registry trial data published/presented - Demonstrated efficacy signal (27.9-month vs. approx. 15-month historical control OS)
  • Registrational Phase III TIGeR-PaC interim analysis expected Q1 ‘23

Broadly applicable to locally advanced solid tumors

  • Initial indications: pancreatic cancer ($1B addressable market) and cholangiocarcinoma
  • Potential future indications include non-small cell lung cancer, uterine tumors, glioblastoma

Novel therapy platform: RenovoTAMP

  • Trans-Arterial Micro-Perfusion compatible with multiple small molecule chemotherapy drugs

RenovoTAMP platform: layers of market exclusivity (regulatory and IP)

  • 8 US patents issued on RenovoTAMP, delivery system, and drug/device combination
  • Orphan Drug Designation for Pancreatic Cancer and Cholangiocarcinoma provides 7 years of market exclusivity for RenovoGem upon NDA approval

Registrational Study in Pancreatic Cancer Ongoing with Follow-on Studies Planned to Expand Market for RenovoGem™


Grab key sources and details from the RNXT company presentation.


And based on these potential breakout catalysts, RNXT requires full focus. Check them out now:

No. 1 RNXT Potential Catalyst - Low Float Could Provide Significant Volatility Potential On Daily Basis

According to the Yahoo Finance website, RNXT has a low float.

The website reports this profile to have approximately 6.18Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

Could positive 2023 company news help provide a near term spark?


No. 2 RNXT Potential Catalyst - Triggered Technicals Galore Across The Short, Medium, And Long Term

At close Tuesday, RNXT was displaying several triggered technical indicators across the short, medium term, and long term.

Barchart was reporting these technical indicators as triggered:

Short Term Indicators

  • 20 Day Moving Average
  • 20 - 50 Day MACD Oscillator
  • 20 - 100 Day MACD Oscillator
  • 20 - 200 Day MACD Oscillator

Medium Term Indicators

  • 50 Day Moving Average
  • 50 - 100 Day MACD Oscillator
  • 50 - 150 Day MACD Oscillator
  • 50 - 200 Day MACD Oscillator

Long Term Indicators

  • 100 Day Moving Average
  • 150 Day Moving Average
  • 200 Day Moving Average
  • 100 - 200 Day MACD Oscillator

The website also shares its all-important "Trend Seeker" composite indicator is triggered, too.

Could this be a signal that RNXT could be gearing up to continue its recent green surge near term?


No. 3 RNXT Potential Catalyst - Game-Changing Results Could Be Only Days Away...

RenovoRx Reports Full Year 2022 Fi-nan-cial Results and Achievement of Important Phase III Clinical Study Milestone

First of Two Planned Interim Analyses Triggered

Company and Data Monitoring Committee Conducting Review

Results of Analysis Forthcoming

LOS ALTOS, Calif., March 02, 2023--(BUSINESS WIRE)--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today is reporting its fi-nan-cial results for the year ended December 31, 2022, and a pipeline update including the status of the interim analysis of for the Company’s Phase III TIGeR-PaC clinical trial.

RenovoRx anticipates finalizing the interim analysis for the TIGeR-PaC Phase III trial and releasing the results within the next week or so. To date, 47 out of 114 target post-SBRT/chemotherapy patients have been randomized in the TIGeR-PaC clinical trial, and the Company has received reports of 26 events (deaths) in this population. This 26th event represents 30% of the 86 events and thus triggered the first planned interim analysis and a meeting of the study’s Data Monitoring Committee ("DMC") to evaluate the ongoing progression of the Phase III clinical trial. Upon completion of the analysis and assessment of the data by the DMC, and RenovoRx’s subsequent review of their findings, the Company will report the first interim analysis.


"RenovoRx has continued to grow in 2022 as we have focused on advancing our innovative therapy platform with the vision of disrupting the current standard of care," said Shaun Bagai, CEO of RenovoRx. "Over the past year, we have advanced our mission to transform oncology therapy with our TIGeR-PaC Phase III study, treating pancreatic cancer, and expanding our clinical pipeline to treat other solid tumors. We have also built a strong internal team, and we look forward to continued progress as we strive to give our patients not just more time but more quality time that they can spend with their loved ones."

Fiscal Year 2022 and Subsequent Operational Highlights:

  • Announced Initial Results in Pharmacokinetic Substudy at the 2023 ASCO Gastrointestinal Cancer Symposium: Data on RenovoGem supports potential for RenovoTAMP therapy platform to increase local gemcitabine delivery and decrease side effects of pancreatic cancer treatment
  • Eighth U.S. patent issued extending the intellectual property coverage of the RenovoTAMP therapy platform
  • Acceptance of four clinical data abstracts at the 2023 ASCO Gastrointestinal Cancer Symposium
  • Presented RenovoTAMP therapy platform at the Advanced Interventional Management Symposium
  • Presented at Symposium on Clinical Interventional Oncology
  • Appointed Angela Gill Nelms as Chief Operating Officer
  • Appointed James Ahlers as Chief Financial Officer
  • Participated in University of Cambridge Academy of Therapeutic Sciences Gateway to Translation Seminar Series
  • Presented preclinical research data demonstrating potential utility for treatment of bile duct cancer
  • Enrolled first pancreatic cancer patient at Columbia University’s New York-Presbyterian Hospital Irving Medical Center in TIGeR-PaC clinical trial study
  • Presented at 2022 SPECTRUM Conference


Read the full article here.


No. 4 RNXT Potential Catalyst - USPTO Issues Company's Eighth US Patent

RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US Patent

Patent broadly covers methods for treating bile duct cancer.

LOS ALTOS, Calif., January 05, 2023--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors, today announced that on January 3, 2023 the United States Patent and Trademark Office issued US patent number 11,541,211 broadly covering methods for treating cholangiocarcinoma (bile duct cancer) by selectively delivering one or more therapeutic agents into targeted regions of the bile duct. This is RenovoRx’s eighth US patent.

"Our newest patent builds upon our strong IP portfolio, which now consists of eight US method and device patents, one EU delivery system patent, and eight additional pending patents in the US, EU, and Asia," said Shaun Bagai, CEO of RenovoRx. "Additionally, this additional patent bolsters the seven years of post-approval market exclusivity that we currently have with our lead oncology product candidate, RenovoGem™, through the Orphan Drug designation granted by the FDA for our first two indications."

Read the full article here.


Nasdaq (RNXT) Recap - These Potential Breakout Catalysts Could Be Huge

No. 1 - Low Float Could Provide Significant Volatility Potential On Daily Basis

No. 2 - Triggered Technicals Galore Across The Short, Medium, And Long Term

No. 3 - Game-Changing Results Could Be Only Days Away...

No. 4 - USPTO Issues Company's Eighth US Patent


Coverage is officially initiated on RNXT. When time permits, do this:


Get RNXT on your radar now.


Kai Parker


(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company. Disclosure: I am not a lice.nsed finan.cial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website and/or reading StockWireNews email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at www.stockwirenews.net/disclosure An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates fierceinvestor . com (“FI”), and owns and operates stockstreetwire . com ("SSW"). From time to time, StockWireNews, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Ownership of "FI" and "SSW" has now moved to a single individual. Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 3/8/23 and ending on 3/9/23 to publicly disseminate information about (RNXT) via Website, Email and SMS. SWN Media LLC was paid two thousand five hundred USD via bank wire transfer. We own zero shares of (RNXT). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and JRZ Capital LLC, TD Media LLC has been hired for a period beginning on 03/06/2023 and ending on 03/10/2023 to publicly disseminate information about (RNXT:US) via digital communications. We have been paid an additional seventy five thousand dollars USD. To date we have been paid one hundred fifty thousand dollars USD to disseminate information about (RNXT:US) via digital communications. We own zero shares of (RNXT:US). lifewatermedia.com/rnxt-disclosure-54/